[Cited FineTest ELISA Kit] Current Research on Breast Cancer Therapy

FineTest ELISA kit contributes to the research on breast cancer therapy. The immunoassay is designed to measure TNF-α and IFN-γ level in serum.

Article Title: Preparation and effects of functionalized liposomes targeting breast cancer tumors using chemotherapy, phototherapy, and immunotherapy
Journal Title: Journal of Nanobiotechnology
DOI: 10.1186/s12951-024-02838-1
IF: 10.6
PMID: 39267061

Abstract: Breast cancer therapy has significantly advanced by targeting the programmed cell death-ligand 1/programmed cell death-1 (PD-L1/PD-1) pathway. BMS-202 (a smallmolecule PD-L1 inhibitor) induces PD-L1 dimerization to block PD-1/PD-L1 interactions, allowing the T-cell-mediated immune response to kill tumor cells. However, immunotherapy alone has limited effects. Clinically approved photodynamic therapy (PDT) activates immunity and selectively targets malignant cells. However, PDT aggravates hypoxia, which may compromise its therapeutic efficacy and promote tumor metastasis. We designed a tumor-specific delivery nanoplatform of liposomes that encapsulate the hypoxia-sensitive antitumor drug tirapazamine (TPZ) and the small-molecule immunosuppressant BMS. New indocyanine green (IR820)-loaded polyethylenimine-folic acid (PEI-FA) was complexed with TPZ and BMS-loaded liposomes via electrostatic interactions to form lipid nanocomposites. This nanoplatform can be triggered by near-infrared irradiation to induce PDT, resulting in a hypoxic tumor environment and activation of the prodrug TPZ to achieve efficient chemotherapy. The in vitro and in vivo studies demonstrated excellent combined PDT, chemotherapy, and immunotherapy effects on the regression of distant tumors and lung metastases, providing a reference method for the preparation of targeted agents for treating breast cancer.

Keywords: Breast cancer, Photodynamic therapy, Immunotherapy, Immune checkpoint blockade, Folate receptor tumor targeting

Immunoassay

Validated Image

Figure Source: J Nanobiotechnology. 2024 Sep 12;22(1):558. doi: 10.1186/s12951-024-02838-1.